Germany and Switzerland set to ease restrictions – as it happened This blog is now closed. The Guardian - UK · Feb 16, 2022
Short AstraZeneca Shelf Life Complicates COVID Vaccine Rollout to World’s Poorest The relatively short shelf life of AstraZeneca Plc's COVID-19 vaccine is complicating the rollout to the world's poorest nations, according to officials and internal World Health Organization documents reviewed by Reuters. It is the latest headache to plague the COVAX vaccine-sharing project, co-led by the WHO and aimed at getting… Asharq Al-Awsat · Feb 16, 2022
Why Are AstraZeneca Shares Trading Higher Today Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease progression in patients with newly diagnosed Benzinga · Feb 15, 2022
Vaccinated people less likely to get long Covid than unvaccinated, new study shows Review finds those who have received two doses of Pfizer/BioNTech, AstraZeneca or Moderna vaccine, or one dose of single-shot J&J vaccine, half as likely to develop long Covid symptoms The Independent UK · Feb 15, 2022
UK pay growth lags behind inflation; company insolvencies rise – as it happened Rolling coverage of the latest economic and financial news The Guardian - UK · Feb 15, 2022
Software firm used by Coca-Cola, the UK Parliament and AstraZeneca acquired Its clients also include Manchester Airports Group, Highways England and Unilever Birmingham Post · Feb 14, 2022
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly Here's a roundup of top developments in the biotech space over the last 24 hours: Benzinga · Feb 10, 2022
AstraZeneca: Q4 Earnings Insights AstraZeneca (NASDAQ:AZN) reported its Q4 earnings results on Thursday, February 10, 2022 at 02:15 AM. Here's what investors need to know about the announcement. Benzinga · Feb 10, 2022
AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21 AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 63% Y/Y to $12.0 Benzinga · Feb 10, 2022
AstraZeneca forecasts higher 2022 sales after record revenues Drugmaker’s total revenues increased by 41% last year with help from $4bn Covid jab income The Guardian - UK · Feb 10, 2022
AstraZeneca Covid jab sales hit £3bn The manufacturer said it expected revenues on coronavirus products to drop in future Wales Online · Feb 10, 2022
AstraZeneca sees $4B in COVID vaccine sales as revenue soars AstraZeneca has recorded a big jump in revenue as it begins to take a profit from its coronavirus vaccine for the first time The Independent UK · Feb 10, 2022
AstraZeneca Covid jab sales rose to £3bn in 2021 The drugs giant swung to a bottom line pre-tax loss of £196m for last year Birmingham Post · Feb 10, 2022
Wall Street drops as interest rate rises loom after US inflation hits 7.5% – as it happened Rolling coverage of the latest economic and financial news The Guardian - UK · Feb 10, 2022
The Guardian - AU · Feb 10, 2022 Covid news: Spain drops mandatory use of face masks outdoors; UK reports another 66,638 daily cases – as it happened Face coverings still required in indoor public spaces in Spain; UK records 66,638 daily infections and 206 Covid-linked deaths
ABC News · Feb 9, 2022 TGA provisionally approves AstraZeneca COVID booster vaccine for Australians aged 18 years and older Australia's medical regulator gives its first green light to the AstraZeneca booster shot for people above the age of 18.
The Independent UK · Feb 9, 2022 How effective are the Pfizer, AstraZeneca and Moderna vaccines against Omicron? Booster jabs provide up to 70 per cent protection, study finds
AAP · Feb 9, 2022 AstraZeneca booster provisionally approved The AstraZeneca booster shot has been provisionally approved by the Therapeutic Goods Administration for people aged 18 and over.
Irish Mirror · Feb 8, 2022 Scientists and politicians 'probably killed hundreds of thousands' by 'damaging AstraZeneca Covid vaccine reputation' Professor Sir John Bell thinks 'bad behaviour' from scientists and politicians 'has probably killed hundreds of thousands of people'
Benzinga · Feb 8, 2022 Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision Medical Second Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc
Pedestrian.tv · Feb 8, 2022 We’ve Officially Got A Fourth Vaccine, So Here’s Everything You Need To Know About Novavax Say hello to Ms Novavax!
The Independent UK · Feb 7, 2022 Single vaccine clinic in Leicester responsible for tenth of known dose wastage across England Exclusive: Other trusts in England have also reported high rates of vaccine wastage
The Guardian - UK · Feb 7, 2022 Harm to AstraZeneca jab’s reputation ‘probably killed thousands’ Scientist who worked on jab criticises ‘bad behaviour’ by scientists and politicians who damaged reputation of Covid vaccine
Evening Standard · Feb 7, 2022 Criticism of AstraZeneca Covid vaccine likely to have killed thousands, says Professor John Bell An Oxford scientist who worked on the AstraZeneca vaccine says he thinks scientists and politicians “probably killed hundreds of thousands of people” by damaging the reputation of the jab.
The Independent UK · Feb 7, 2022 Criticism of AstraZeneca jab ‘probably killed hundreds of thousands,’ claims scientist Professor Sir John Bell said ‘they have damaged the reputation of the vaccine in a way that echoes around the rest of the world’